| 60.17 1.21 (2.05%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 72.67 |
1-year : | 84.88 |
| Resists | First : | 62.22 |
Second : | 72.67 |
| Pivot price | 59.18 |
|||
| Supports | First : | 58.65 |
Second : | 56.45 |
| MAs | MA(5) : | 58.63 |
MA(20) : | 58.89 |
| MA(100) : | 56.49 |
MA(250) : | 49.91 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 35.6 |
D(3) : | 28.1 |
| RSI | RSI(14): 55.2 |
|||
| 52-week | High : | 62.88 | Low : | 41.88 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BMY ] has closed below upper band by 27.0%. Bollinger Bands are 18.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 60.56 - 60.8 | 60.8 - 61.04 |
| Low: | 57.94 - 58.2 | 58.2 - 58.46 |
| Close: | 59.73 - 60.16 | 60.16 - 60.57 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Sat, 18 Apr 2026
Farther Finance Advisors LLC Has $4.22 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Sat, 18 Apr 2026
Assetmark Inc. Lowers Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Fri, 17 Apr 2026
Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff - Seeking Alpha
Fri, 17 Apr 2026
A Look At Bristol Myers Squibb (BMY) Valuation As Undervaluation Debate Resurfaces - simplywall.st
Fri, 17 Apr 2026
Wright Investors Service Inc. Has $5.64 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Fri, 17 Apr 2026
Bristol Myers Squibb Company $BMY Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 2,040 (M) |
| Held by Insiders | 2.03e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 31,670 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 392.1 |
| Profit Margin | 14.6 % |
| Operating Margin | 28.1 % |
| Return on Assets (ttm) | 10.2 % |
| Return on Equity (ttm) | 40.4 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 1.2963e+011 |
| Sales Per Share | 1.78481e+011 |
| EBITDA (p.s.) | 7.08148e+010 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 14,160 (M) |
| PE Ratio | 17.39 |
| PEG Ratio | 0 |
| Price to Book value | 0.15 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.79 |
| Dividend | 0 |
| Forward Dividend | 2.985e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|